- Home
- SPFI vs KURA Comparison
SPFI vs KURA Comparison
Compare SPFI & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$7.77
Company Overview
Basic Information| Metric | SPFI | KURA |
|---|---|---|
| Founded | 1941 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 632.4M | 744.0M |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SPFI | KURA |
|---|---|---|
| Price | $41.25 | $7.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $44.00 | $25.88 |
| AVG Volume (30 Days) | 84.0K | ★ 1.3M |
| Earning Date | 04-23-2026 | 03-05-2026 |
| Dividend Yield | ★ 1.62% | N/A |
| EPS Growth | ★ 17.81 | N/A |
| EPS | ★ 3.44 | N/A |
| Revenue | N/A | ★ $67,482,000.00 |
| Revenue This Year | $22.65 | $62.31 |
| Revenue Next Year | $9.40 | $58.09 |
| P/E Ratio | $12.17 | ★ N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $30.01 | $5.41 |
| 52 Week High | $44.00 | $12.49 |
Technical Indicators
Market Signals| Indicator | SPFI | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 49.66 | 36.89 |
| Support Level | $39.49 | $7.36 |
| Resistance Level | $41.91 | $10.50 |
| Average True Range (ATR) | 1.05 | 0.38 |
| MACD | 0.08 | -0.08 |
| Stochastic Oscillator | 62.28 | 3.21 |
Price Performance
Historical Comparison SPFI
KURA
About SPFI South Plains Financial Inc.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.